Developing new treatments for COVID-19
Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
['FUNDING_OTHER'] · FOX CHASE CHEMICAL DIVERSITY CENTER, INC · NIH-10688262
This study is working on new medicines that can help fight COVID-19 by blocking the virus from spreading in the body, which could lead to better treatments for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FOX CHASE CHEMICAL DIVERSITY CENTER, INC (nih funded) |
| Locations | 1 site (DOYLESTOWN, UNITED STATES) |
| Trial ID | NIH-10688262 on ClinicalTrials.gov |
What this research studies
This research focuses on creating small molecule compounds that target the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19. The approach involves understanding how the virus interacts with specific host proteins to facilitate its spread and developing antiviral agents that can disrupt these interactions. By targeting these mechanisms, the research aims to provide effective treatments against SARS-CoV-2 and its emerging variants. Patients may benefit from new antiviral therapies that could reduce the severity of COVID-19 infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of severe COVID-19 infection or those who have tested positive for SARS-CoV-2.
Not a fit: Patients who are not infected with SARS-CoV-2 or those who have already recovered from COVID-19 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new antiviral treatments that significantly improve outcomes for patients infected with COVID-19.
How similar studies have performed: Other research has shown promise in developing antiviral agents targeting similar mechanisms in viral infections, indicating a potential for success in this novel approach.
Where this research is happening
DOYLESTOWN, UNITED STATES
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC — DOYLESTOWN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HARTY, RONALD N — FOX CHASE CHEMICAL DIVERSITY CENTER, INC
- Study coordinator: HARTY, RONALD N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.